| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2565 | 2010 |
| Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore-Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008 | 2153 | 2008 |
| PI3K/AKT signaling pathway and cancer: an updated review M Martini, MC De Santis, L Braccini, F Gulluni, E Hirsch Annals of medicine 46 (6), 372-383, 2014 | 1145 | 2014 |
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009 | 924 | 2009 |
| Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, ... PloS one 4 (10), e7287, 2009 | 320 | 2009 |
| Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer C Costa, H Ebi, M Martini, SA Beausoleil, AC Faber, CT Jakubik, A Huang, ... Cancer cell 27 (1), 97-108, 2015 | 205 | 2015 |
| PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function I Franco, F Gulluni, CC Campa, C Costa, JP Margaria, E Ciraolo, ... Developmental cell 28 (6), 647-658, 2014 | 203 | 2014 |
| Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth M Li, V Sala, MC De Santis, J Cimino, P Cappello, N Pianca, A Di Bona, ... Circulation 138 (7), 696-711, 2018 | 163 | 2018 |
| Targeted therapies: how personal should we go? M Martini, L Vecchione, S Siena, S Tejpar, A Bardelli Nature reviews Clinical oncology 9 (2), 87-97, 2012 | 142 | 2012 |
| Targeting PI3K in cancer: any good news? M Martini, E Ciraolo, F Gulluni, E Hirsch Frontiers in oncology 3, 108, 2013 | 131 | 2013 |
| Class II PI3K functions in cell biology and disease F Gulluni, MC De Santis, JP Margaria, M Martini, E Hirsch Trends in cell biology 29 (4), 339-359, 2019 | 120 | 2019 |
| Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses F Di Nicolantonio, S Arena, M Gallicchio, D Zecchin, M Martini, SE Flonta, ... Proceedings of the National Academy of Sciences 105 (52), 20864-20869, 2008 | 114 | 2008 |
| Targeting PI3K signaling in cancer: Challenges and advances MC De Santis, F Gulluni, CC Campa, M Martini, E Hirsch Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1871 (2), 361-366, 2019 | 79 | 2019 |
| PI3K in cancer–stroma interactions: bad in seed and ugly in soil E Hirsch, E Ciraolo, I Franco, A Ghigo, M Martini Oncogene 33 (24), 3083-3090, 2014 | 78 | 2014 |
| Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function F Gulluni, M Martini, MC De Santis, CC Campa, A Ghigo, JP Margaria, ... Cancer Cell 32 (4), 444-459. e7, 2017 | 77 | 2017 |
| Signaling pathways regulating redox balance in cancer metabolism MC De Santis, PE Porporato, M Martini, A Morandi Frontiers in oncology 8, 126, 2018 | 65 | 2018 |
| PI (3, 4) P2 signaling in cancer and metabolism L Gozzelino, MC De Santis, F Gulluni, E Hirsch, M Martini Frontiers in oncology 10, 360, 2020 | 64 | 2020 |
| Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia A Bottos, M Martini, F Di Nicolantonio, V Comunanza, F Maione, ... Proceedings of the National Academy of Sciences 109 (6), E353-E359, 2012 | 59 | 2012 |
| PI3K keeps the balance between metabolism and cancer L Braccini, E Ciraolo, M Martini, T Pirali, G Germena, K Rolfo, E Hirsch Advances in biological regulation 52 (3), 389-405, 2012 | 54 | 2012 |
| Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer M Mortazavi, F Moosavi, M Martini, E Giovannetti, O Firuzi Critical reviews in oncology/hematology 176, 103749, 2022 | 47 | 2022 |
